Combination Statin/Metformin And Prostate Cancer Specific Mortality: A Population-Based Study.

5018 Background: Obesity and metabolic syndromes (MetS) are associated with an increased risk of prostate cancer mortality. A recent pre-clinical study showed that combination statin /metformin (CSM) was more effective in inhibiting metastasis than standard chemotherapy (docetaxel) with less toxicity in an in vivo model. As clinical data on this topic are limited, this population-based study is to examine the association between treatment with CSM and prostate cancer specific mortality (PCSM) by obesity/MetS status. Methods: SEER-Medicare linked data were used to identify patients with high-risk prostate cancer (stage T3/T4 or PSAu003e20 or Gleason 8-10) in 2007 – 2009. Prescription drug use was identified from Medicare Part D Event files. Obesity/MetS conditions were identified by the presence of ICD-9 diagnosis codes 278.00, 278.01, or 277.7. Cox proportional hazards models were used to compare PCSM with covariates including demographic characteristics, prognostic factors, and cancer treatment(s) received. ...